Your SlideShare is downloading. ×
Managing both nasal and ocular symptoms in patients
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Managing both nasal and ocular symptoms in patients

218
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
218
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Managing both nasal and ocular symptoms in patients with moderate to severe seasonal allergic rhinitis (SAR)
    “When we think about allergic rhinitis, we forget that the eyes come along.”
    http://kardzmed.com
    OBJECTIVE:
  • 2. that about 75% of the most severe SAR patients complain of itchy eyes and about two thirds of them complain of watery eyes
    there's been a lot of interest in looking at combinations of nasal antihistamines and nasal corticosteroids, with previous studies showing that the combination is more effective statistically than the single entities
    http://kardzmed.com
    Basis of Research
  • 3. Paul Ratner, MD, allergist/immunologist and founder and director of Sylvana Research, of San Antonio, Texas, a research facility for investigational medications.
    http://kardzmed.com
    Lead Reasearcher
  • 4. the ocular effects from treatment with this combination.
    http://kardzmed.com
    Aim of study“Treat the Eyes and the Nose”
  • 5. His investigational team enrolled 610 patients with ocular symptoms from SAR during the 2007/08 Texas Mountain Cedar season.
    The patients were randomized to 1 of 4 groups receiving 1 spray per nostril twice daily: azelastine alone, fluticasone alone, azelastine plus fluticasone, and placebo.
    http://kardzmed.com
    Procedure
  • 6. The primary end point was efficacy, defined as a change from baseline in the total nasal symptom score (TNSS) for nasal congestion, sneezing, itchy nose, and runny nose.
    The secondary end point was the effect of azelastine plus fluticasone on the total ocular symptom score (TOSS) for itchy eyes, watery eyes, and redness
    http://kardzmed.com
    Set objectives to investigate
  • 7. Results were presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2009 Annual Scientific Meeting in a podium session
    http://kardzmed.com
    Results
  • 8. Nasal and Ocular Symptoms Improved
    improvements on TNSS were statistically significant for the patients treated with the combination spray compared with single drug
    http://kardzmed.com
    1. TNSS
  • 9. There was also a statistically significant improvement in TOSS for those treated with the combination spray
    http://kardzmed.com
    2. TOSS
  • 10. The only adverse events reported by more than 2% of those treated with the combination spray were
    bitter taste (7.2%),
    epistaxis(3.9%),
    and headache (2.6%).
    http://kardzmed.com
    adverse effects
  • 11. The first is that the combination therapy with nasal antihistamines and nasal steroids is definitely panning out to be more effective than treatment with the individual components
    Second, in addition to treating the nasal symptoms that you would expect, you're also getting the added benefit of having relief of the ocular symptoms."
    http://kardzmed.com
    Conclusion
  • 12. allergists are now using both drugs in combination in 30% to 40% of their patients.
    So what this study reinforces is that polypharmacy, using an antihistamine blocker as well as a nasal steroid, may be a more effective modality in treating this ocular complaint and the nasal symptoms
    http://kardzmed.com
  • 13. This study was funded by Meda pharmaceuticals
    November 13, 2009 (San Diego, California)
    Presented in ENT class (Ml410)
    by Dr. Karl
    http://kardzmed.com
    http://kardzmed.com
    THE END